Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Añadir filtros








Intervalo de año
1.
Mem. Inst. Oswaldo Cruz ; 110(4): 534-542, 09/06/2015. graf
Artículo en Inglés | LILACS | ID: lil-748872

RESUMEN

Hepatitis C virus (HCV) envelope protein 2 (E2) is involved in viral binding to host cells. The aim of this work was to produce recombinant E2B and E2Y HCV proteins in Escherichia coli and Pichia pastoris, respectively, and to study their interactions with low-density lipoprotein receptor (LDLr) and CD81 in human umbilical vein endothelial cells (HUVEC) and the ECV304 bladder carcinoma cell line. To investigate the effects of human LDL and differences in protein structure (glycosylated or not) on binding efficiency, the recombinant proteins were either associated or not associated with lipoproteins before being assayed. The immunoreactivity of the recombinant proteins was analysed using pooled serum samples that were either positive or negative for hepatitis C. The cells were immunophenotyped by LDLr and CD81 using flow cytometry. Binding and binding inhibition assays were performed in the presence of LDL, foetal bovine serum (FCS) and specific antibodies. The results revealed that binding was reduced in the absence of FCS, but that the addition of human LDL rescued and increased binding capacity. In HUVEC cells, the use of antibodies to block LDLr led to a significant reduction in the binding of E2B and E2Y. CD81 antibodies did not affect E2B and E2Y binding. In ECV304 cells, blocking LDLr and CD81 produced similar effects, but they were not as marked as those that were observed in HUVEC cells. In conclusion, recombinant HCV E2 is dependent on LDL for its ability to bind to LDLr in HUVEC and ECV304 cells. These findings are relevant because E2 acts to anchor HCV to host cells; therefore, high blood levels of LDL could enhance viral infectivity in chronic hepatitis C patients.


Asunto(s)
Animales , Bovinos , Humanos , /fisiología , Células Endoteliales/virología , Hepacivirus/inmunología , Receptores de LDL/fisiología , Proteínas del Envoltorio Viral/fisiología , /inmunología , Línea Celular , Escherichia coli , Células Endoteliales/inmunología , Citometría de Flujo , Proteínas de la Membrana , Pichia , Proteínas Recombinantes , Receptores de LDL/inmunología
2.
Braz. j. med. biol. res ; 41(12): 1086-1092, Dec. 2008. ilus, graf
Artículo en Inglés | LILACS | ID: lil-502158

RESUMEN

In order to determine the effect of antibodies against electronegative low-density lipoprotein LDL(-) on atherogenesis, five groups of LDL low receptor-deficient (LDLr-/-) mice (6 per group) were immunized with the following antibodies (100 µg each): mouse anti-LDL(-) monoclonal IgG2b, rabbit anti-LDL(-) polyclonal IgG or its Fab fragments and mouse irrelevant monoclonal IgG and non-immunized controls. Antibodies were administered intravenously one week before starting the hypercholesterolemic diet (1.25 percent cholesterol) and then every week for 21 days. The passive immunization with anti-LDL(-) monoclonal IgG2b, polyclonal antibody and its derived Fab significantly reduced the cross-sectional area of atherosclerotic lesions at the aortic root of LDLr-/- mice (28.8 ± 9.7, 67.3 ± 17.02, 56.9 ± 8.02 µm² (mean ± SD), respectively) compared to control (124.9 ± 13.2 µm²). Vascular cell adhesion molecule-1 protein expression, quantified by the KS300 image-analyzing software, on endothelium and the number of macrophages in the intima was also decreased in aortas of mice treated with anti-LDL(-) monoclonal antibody (3.5 ± 0.70 per field x 10) compared to controls (21.5 ± 3.5 per field x 10). Furthermore, immunization with the monoclonal antibody decreased the concentration of LDL(-) in blood plasma (immunized: 1.0 ± 1.4; control: 20.5 ± 3.5 RLU), the amount of cholesterol oxides in plasma (immunized: 4.7 ± 2.7; control: 15.0 ± 2.0 pg COx/mg cholesterol) and liver (immunized: 2.3 ± 1.5; control: 30.0 ± 26.0 pg COx/mg cholesterol), and the hepatic content of lipid hydroperoxides (immunized: 0.30 ± 0.020; control: 0.38 ± 0.15 ng/mg protein). In conclusion, antibodies against electronegative LDL administered intravenously may play a protective role in atherosclerosis.


Asunto(s)
Animales , Femenino , Ratones , Conejos , Anticuerpos Monoclonales/administración & dosificación , Aterosclerosis/terapia , Inmunización Pasiva/métodos , Inmunoglobulina G/administración & dosificación , Lipoproteínas LDL/administración & dosificación , Receptores de LDL/inmunología , Anticuerpos Monoclonales/inmunología , Aterosclerosis/inmunología , Aterosclerosis/metabolismo , Inmunohistoquímica , Fragmentos Fab de Inmunoglobulinas/administración & dosificación , Fragmentos Fab de Inmunoglobulinas/inmunología , Inmunoglobulina G/inmunología , Peroxidación de Lípido/inmunología , Lipoproteínas LDL/inmunología , Receptores de LDL/metabolismo , Molécula 1 de Adhesión Celular Vascular/inmunología
3.
Braz. j. med. biol. res ; 41(1): 1-4, Jan. 2008.
Artículo en Inglés | LILACS | ID: lil-469973

RESUMEN

This essay proposes that the ecologic association shown between the 20th century coronary heart disease epidemic and the 1918 influenza pandemic could shed light on the mechanism associated with the high lethality of the latter. It suggests that an autoimmune interference at the apoB-LDL interface could explain both hypercholesterolemia and inflammation (through interference with the cellular metabolism of arachidonic acid). Autoimmune inflammation, then, would explain the 1950s-60s acute coronary events (coronary thrombosis upon influenza re-infection) and the respiratory failure seen among young adults in 1918. This hypothesis also argues that the lethality of the 1918 pandemic may have not depended so much on the 1918 virus as on an immune vulnerability to it, possibly resulting from an earlier priming of cohorts born around 1890 by the 1890 influenza pandemic virus.


Asunto(s)
Animales , Historia del Siglo XX , Humanos , Enfermedad Coronaria/mortalidad , Brotes de Enfermedades , Gripe Humana/mortalidad , Apolipoproteínas B/inmunología , Autoanticuerpos/inmunología , Enfermedades Autoinmunes/inmunología , Autoinmunidad/inmunología , Enfermedad Coronaria/historia , Enfermedad Coronaria/inmunología , Susceptibilidad a Enfermedades , Brotes de Enfermedades/historia , Brotes de Enfermedades/estadística & datos numéricos , Hipercolesterolemia/inmunología , Inflamación/inmunología , Gripe Humana/historia , Gripe Humana/inmunología , Lipoproteínas LDL/inmunología , Recurrencia , Receptores de LDL/inmunología
4.
Journal of Huazhong University of Science and Technology (Medical Sciences) ; (6): 205-7, 2004.
Artículo en Inglés | WPRIM | ID: wpr-634138

RESUMEN

The polyclonal antibodies against VLDL receptor were prepared and identified. Rabbits were immunized with polypeptide fragment of VLDL receptor as antigen. The collected blood serum of the immunized rabbits was analyzed and identified by using ELISA and Western Blot. The results showed that the rabbit against mouse and human VLDL receptor antibodies were obtained with high titer and could recognize the natural VLDL receptors through Western blot. The prepared polyclonal antibodies against VLDL receptor provide a new tool to study the protein of VLDL receptor.


Asunto(s)
Anticuerpos/química , Anticuerpos/inmunología , Ensayo de Inmunoadsorción Enzimática , Péptidos/inmunología , Receptores de LDL/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA